5,871 followers
New Research: Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study) #pharmacology https://t.co/BUPgL16x